Targeting CD24 as a novel immunotherapy for solid cancers

Cell Commun Signal. 2023 Nov 2;21(1):312. doi: 10.1186/s12964-023-01315-w.

Abstract

Cluster of differentiation 24 (CD24), a mucin-like highly glycosylated molecule has been extensively studied as a cancer stem cell marker in a variety of solid cancers. The functional role of CD24 is either fulfilled by combining with ligands or participating in signal transduction, which mediate the initiation and progression of neoplasms. Recently, CD24 was also described as an innate immune checkpoint with apparent significance in several types of solid cancers. Herein, we review the current understanding of the molecular fundamentals of CD24, the role of CD24 in tumorigenesis and cancer progression, the possibility as a promising therapeutic target and summarized different therapeutic agents or strategies targeting CD24 in solid cancers. Video Abstract.

Keywords: CD24; Cancer Stem Cells; Cell signaling; Immune checkpoint inhibitors; Immunotherapy; Solid cancer.

Publication types

  • Video-Audio Media
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD24 Antigen / metabolism
  • Humans
  • Immunotherapy
  • Ligands
  • Neoplasms* / therapy
  • Signal Transduction

Substances

  • Ligands
  • CD24 Antigen
  • CD24 protein, human